MADISON, Wis.–(BUSINESS WIRE)–Venture Investors Health Fund, one of the Midwest’s longest-standing healthcare-focused venture firms, today announced its rebrand to Clarevia Ventures, a new name that reflects the firm’s sharpened focus on helping early-stage medtech and life sciences companies navigate the path from breakthrough science to patient impact.
The rebrand comes after years of evolution within the firm. While Clarevia has invested exclusively in healthcare since 2018, the new identity signals a clearer articulation of what the team has become over time: a healthcare venture firm focused not only on capital, but also on the strategic, clinical, and operational rigor required to build enduring companies in a more complex market.
“Clarevia reflects where we’ve been heading for years,” said Jim Adox, Managing Partner at Clarevia Ventures. “Healthcare innovation has become more technical, more regulated, and more demanding at the earliest stages. Founders need more than capital. They need experienced partners who can help them make the right decisions early, when clarity matters most.”
Founded in 1984, the firm began as a generalist investor with deep roots in the Midwest. Over four decades, it built a record of producing strong healthcare exits, developed longstanding partnerships with research institutions such as the University of Wisconsin–Madison and the University of Michigan, and expanded its network and impact globally. The new name, Clarevia, reflects that evolution and the role the firm believes it plays for founders today: helping bring clarity, focus, and momentum to companies tackling difficult healthcare challenges.
The timing also reflects what the team sees in the market. As healthcare companies face rising clinical, regulatory, and commercialization demands, early decisions carry outsized consequences.
“In healthcare, lack of clarity early can be lethal,” said Jenni Le, Principal at Clarevia Ventures. “If a company does not have a clear view of the problem, the regulatory path, and the milestones that matter, mistakes become expensive very quickly. That is why having the right partner at the table early makes such a meaningful difference.”
“As we meet more founders working at the intersection of AI, data, and healthcare, our relationships and experience help bring clarity to the regulatory and pre-clinical decisions that matter early,” said Paul Weiss, PhD., Partner at Clarevia Ventures.
Clarevia points to companies such as HistoSonics, EarliPoint, EnsoData, Neurovance, and others across its recent funds as proof of that model in practice: partnering early, helping sharpen strategy, recruiting experienced talent, and staying engaged through the long path of company building.
“This is not about becoming something new overnight,” said David Arnstein, Partner and CFO at Clarevia Ventures. “It is about putting a clearer name to the firm we have become, and to the kind of partner we intend to be for founders going forward.”
About Clarevia Ventures
Clarevia is a venture capital firm dedicated to turning scientific breakthroughs into life-changing patient outcomes. Founded in 1984, Clarevia partners with founders at the earliest and most overlooked stages, providing the capital, operational rigor, and counsel to usher promising science from discovery to commercialization. Behind companies such as HistoSonics, Neurovance and EarliPoint, Clarevia’s mission is to ensure the most important healthcare innovations find a clear path to the patients who need them most.
Contacts
Press Contact
Kayla Liederbach
[email protected]
